Alami, A.; Villeneuve, P.J.; Farrell, P.J.; Mattison, D.; Farhat, N.; Haddad, N.; Wilson, K.; Gravel, C.A.; Crispo, J.A.G.; Perez-Lloret, S.;
et al. Myocarditis and Pericarditis Post-mRNA COVID-19 Vaccination: Insights from a Pharmacovigilance Perspective. J. Clin. Med. 2023, 12, 4971.
https://doi.org/10.3390/jcm12154971
AMA Style
Alami A, Villeneuve PJ, Farrell PJ, Mattison D, Farhat N, Haddad N, Wilson K, Gravel CA, Crispo JAG, Perez-Lloret S,
et al. Myocarditis and Pericarditis Post-mRNA COVID-19 Vaccination: Insights from a Pharmacovigilance Perspective. Journal of Clinical Medicine. 2023; 12(15):4971.
https://doi.org/10.3390/jcm12154971
Chicago/Turabian Style
Alami, Abdallah, Paul J. Villeneuve, Patrick J. Farrell, Donald Mattison, Nawal Farhat, Nisrine Haddad, Kumanan Wilson, Christopher A. Gravel, James A. G. Crispo, Santiago Perez-Lloret,
and et al. 2023. "Myocarditis and Pericarditis Post-mRNA COVID-19 Vaccination: Insights from a Pharmacovigilance Perspective" Journal of Clinical Medicine 12, no. 15: 4971.
https://doi.org/10.3390/jcm12154971
APA Style
Alami, A., Villeneuve, P. J., Farrell, P. J., Mattison, D., Farhat, N., Haddad, N., Wilson, K., Gravel, C. A., Crispo, J. A. G., Perez-Lloret, S., & Krewski, D.
(2023). Myocarditis and Pericarditis Post-mRNA COVID-19 Vaccination: Insights from a Pharmacovigilance Perspective. Journal of Clinical Medicine, 12(15), 4971.
https://doi.org/10.3390/jcm12154971